key: cord-0054415-1i9mxvkj
authors: Medranda, Giorgio A.; Case, Brian C.; Wermers, Jason P.; Morrison, Natalie; Yerasi, Charan; Forrestal, Brian; Chezar-Azerrad, Chava; Waksman, Ron
title: Review of imaging and physiology late breaking trials from the TCT connect 2020 virtual meeting
date: 2021-01-04
journal: Cardiovasc Revasc Med
DOI: 10.1016/j.carrev.2020.12.037
sha: b07a8c07796cfdae7c02c8393cf2e5cabb885297
doc_id: 54415
cord_uid: 1i9mxvkj

• ACC Scientific Sessions 2020 shared the latest research in cardiology. • We highlight results from 14 late-breaking trials. • Areas covered include TAVR, coronary, and peripheral artery disease.

Virtual meetings continue to replace in-person meetings across the world amidst the coronavirus disease 2019 (COVID-19) pandemic. Despite this, highly anticipated clinical research continues to be presented, with broader audiences no longer limited by distance or cost. In this article, we present a brief overview of the imaging and physiology late-breaking clinical trials presented at the Transcatheter Cardiovascular Therapeutics (TCT) Connect 2020 virtual conference that carry significant clinical implications. The primary and major secondary endpoints were the covariate-adjusted relationship between lipid-rich plaques, defined as those with the highest quartile of the NIRS-defined maximum Lipid Core Burden Index over a 4-mm length (maxLCBI 4mm ) and patient-level and lesion-level major adverse cardiovascular events (MACE), respectively. The researchers also assessed the maxLCBI 4mm cutoff of 400 or more as a secondary sensitivity analysis. IVUS-defined parameters of plaque burden of 70% or more and MLA of 4 mm 2 or less were also assessed to identify highrisk vulnerable plaque. Subsequent MACE, either requiring revascularization or with rapid lesion progression, were then monitored on the basis of follow-up angiography arising from either originally treated culprit or untreated non-culprit lesions.

The researchers found that adverse events within 4 years occurred in 13.2% of patients, with the highest percentage of events (8%) arising from untreated non-culprit lesions with a mean J o u r n a l P r e -p r o o f Journal Pre-proof baseline diameter stenosis of 46.9%. PROSPECT II showed that patients with a high plaque burden had a threefold increase in patient-level risk (odds ratio [OR], 3.09; 95% confidence interval [CI]: 1.65, 5.76), and an 11-fold increase in lesion-level risk (OR, 11.37; 95% CI: 5.60, 23.11). Those with high-lipid plaques had patient risk doubled from 4.8% to 10.1%, and on the lesion level a sevenfold increase, from 0.5% to 3.8%.

NIRS-IVUS-identified plaques with both high lipid content and high plaque burden had a substantially higher risk, with 7% MACE risk at the lesion level. Furthermore, the investigators found that having neither high plaque burden nor high lipid level in a plaque resulted in a very low risk of events (0.2%). During the presentation, Erlinge said the findings should at least prompt treatment of patients found to have these kind of "high-risk" plaques with lipid-lowering therapy and implement a preventative strategy. He and fellow researchers now call for further studies prospectively using this information to improve outcomes for high-risk patients with coronary artery disease (CAD).

The study received funding from Abbott Medical Devices, InfraReDx, and The Medicines p=0.02). This advantage was sustained at 3 years (6.6% vs. 10.7%; HR, 0.60; 95% CI: 0.42, 0.87; p=0.01), largely driven by clinically driven target vessel revascularization (4.5% vs. 6.9%; HR, 0.64; 95% CI: 0.41, 1.00; p=0.05). Finally, a comparison of optimal vs. suboptimal PCI showed a significantly lower TVF rate in patients who underwent optimal PCI (4.2% vs. 9.2%; patient safety. Observational findings from the UK health technology assessment (HTA) body, the National Institute for Health and Care Excellence (NICE), the authority that issues guidance over interventions for reimbursement for the National Health Service (NHS) England and Wales, also suggest that financial savings could be made through use of CTCA and FFR-CT as a frontline strategy. NICE, therefore, already recommends FFR-CT in routine clinical practice, although the clinical effectiveness and economic impact of this compared to other tests in the evaluation of stable chest pain had not previously been tested in a randomized trial.

The FORECAST randomized trial was aimed at addressing this, laying out the economic as well as clinical impact of non-invasive cardiac tests, including FFR-CT compared with routine options such as ICA, coronary revascularization, hospitalization for a cardiac event, and cardiac medications. The primary endpoint was total cardiac medical cost through 9 months. Secondary However, the proportion of patients with a final FFR score of 0.80 or less was 18.6% in the PIOS group versus 29.8% in the control group, significantly lower at 11.2 percentage points (p=0.045).

Based on FFR pullback assessment of the stented vessel in the PIOS group, a target for further optimization was found in 60 of the 131 patients (46%). Operators considered it appropriate to perform additional post-dilation core stenting in 40 of these 60 patients. Of those who had further intervention or optimization performed, the mean post-PCI FFR increased from 0.76 to 0.82, with a rise in mean coronary flow reserve (CFR) from 3 to 4.

TARGET FFR did not hit its primary endpoint of achieving an FFR of 0.90 or higher post-PCI with a physiologically guided optimization strategy, but it did significantly increase the proportion of patients with a final FFR of 0.80 or less compared to standard care. Post-PCI FFR values of 0.90 or higher are linked to an improved cardiac prognosis, while the guidelinedirected revascularization threshold cited in the study was 0.80 or less. Nevertheless, despite shock aired during the expert panel discussion at the press conference concerning the surprisingly high percentage of patients with suboptimal FFR levels post-PCI, Collison questioned how realistic it is to target 0.90 or more, noting wide variation in PCI practice.

The trial was funded by the UK's NHS National Waiting Times Centre Board endowment funds.

Presenter: Dr. Nils Johnson J o u r n a l P r e -p r o o f FFR-/CFR-was 5.0% (95% CI: -1.5%, 11.5%; p = 0.065 for non-inferiority). Therefore, the study found that vessels with abnormal FFR ≤0.8 but intact CFR ≥2 did not have non-inferior outcomes compared to FFR >0.8 and CFR ≥2 when treated medically. FFR+/CFRfailed to meet noninferiority, meaning that the FFR cutoff still holds, regardless of the CFR reading. These findings are interesting, but given the observational nature of the study, they come with limitations, as subjects and physicians were unblinded in this study.

The DEFINE-FLOW trial was funded by Philips (previously Volcano Corporation).

J o u r n a l P r e -p r o o f

Medical School at UT Health (Houston) and Memorial Hermann Hospital

All other combinations, including FFR ≤0.8 but intact CFR >2.0 (termed CFR-), received initial medical therapy. FFR >0.8 was termed FFR-. The primary endpoint was MACE, a composite of all-cause death, myocardial infarction, and any revascularization at 2 years with a non-inferiority margin of 10%. The study findings for MACE were 5

A Prospective Natural History Study Using NIRS-IVUS Imaging in Patients With Acute Myocardial Infarction

A Prospective Natural History Study Using OCT Imaging in Patients With Diabetes

ULTIMATE: Three-Year Outcomes After IVUS-Guided vs Angiography Guided DES Implantation

Three-Year Outcomes of the ULTIMATE Trial Comparing Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation

One-Year Outcomes in Patients With Post-PCI Residual Ischemia

FORECAST: A Randomized Trial of CTA/FFRCT Decision-making in Patients With Chest Pain

A Randomized Trial of Physiology-Guided PCI Optimization

DEFINE-FLOW: An Observational Study of Deferred Lesions After FFR and CFR Assessment